Genomics: Why the Next Wave of Healthcare Innovation Could Be Written in Our DNA

Genomics is moving beyond the laboratory into a broader commercial opportunity across healthcare. Advances in sequencing, genomic analysis, diagnostics and gene editing are creating new ways to understand disease, identify patients and develop treatments, while artificial intelligence is increasingly being used to process and interpret growing volumes of biological data. This is creating opportunities across the infrastructure used to generate genomic data, the technologies used to interpret it, diagnostics built around it and therapies designed to act on the underlying biology. For investors, the more relevant question is not whether genomics has potential, but where that potential can translate into durable commercial value.

What Genomics Actually Is

Genetics is the study of individual genes and how genetic variations influence traits and disease. Genomics is broader. It looks at the entire genome, the complete set of an organism's DNA, and how its many components interact with each other and with the wider biological system.

That difference sounds academic, but it is the reason the field has become commercially interesting. Studying one gene can answer a narrow question. Reading an entire genome produces a dataset that can be compared, analysed and modelled against information from thousands or millions of other samples.

The result is that genomics has moved well beyond understanding DNA. Genomic information is now used to diagnose disease, select treatments, guide drug development and, in a small but growing number of cases, to act directly on the underlying biology.

Why Genomics Is Gaining Momentum

Three developments are changing the commercial potential of genomics at the same time.

The first is cost and capability. Advances in sequencing technology have substantially reduced the cost of generating genomic information while improving accuracy, speed and throughput. That has helped move genomic analysis from a specialist research exercise towards a technology with increasingly broad applications across research and healthcare.

The second is interpretation, and this is where the more interesting commercial question sits. Generating genomic data is becoming easier, but extracting useful information from it remains difficult. A human genome contains billions of base pairs, and identifying which variations matter clinically is a data problem as much as a biological one.

This is where AI becomes increasingly relevant. Machine learning can help identify patterns, interpret variants, identify biomarkers and accelerate aspects of drug discovery. The convergence is straightforward: genomics generates the biological data, while AI increasingly provides the tools to interpret it.

The third is clinical adoption. Precision medicine has moved from a research concept towards established clinical use in defined areas, particularly oncology and rare disease. Adoption is what converts technological capability into a commercial market.

There is a useful parallel with AI. The value created by AI has not been limited to the companies developing the most visible models. It has spread across infrastructure, data, software and applications. Genomics has a similar structure, creating opportunities at multiple points between generating biological information and turning it into a clinical or therapeutic outcome.

The Genomics Value Chain

Genomics is not a single industry. It is a chain of businesses with different customers, revenue models, capital requirements and risk profiles. The progression runs from generating genomic data, to interpreting it, to turning it into a clinical decision, to developing treatments that act on what was found.

Infrastructure. Companies such as Illumina (NASDAQ: ILMN), Oxford Nanopore Technologies (LSE: ONT) and Twist Bioscience (NASDAQ: TWST) supply the instruments, reagents and synthetic DNA that make everything downstream possible. The economics resemble other tools businesses: an instrument sale is lumpy and competitive, while the consumables that run through an installed base recur. Installed base size and consumable pull-through matter more to earnings quality here than headline instrument orders.

Single-cell and spatial biology. 10x Genomics (NASDAQ: TXG) provides technologies that allow researchers to analyse biological systems at much greater resolution, including individual cells and their location within tissue. This represents an expansion of the genomics opportunity beyond sequencing towards more detailed analysis of biological systems.

Data and precision medicine. Tempus AI (NASDAQ: TEM) combines genomic information, clinical records and AI-driven analytics. Its model illustrates the potential value of moving beyond generating genomic data to interpreting it and turning it into commercially useful information. In the quarter ended 30 June 2026, Tempus reported revenue of USD382.5 million, up 22% year on year, while oncology testing volumes increased 31% and data licensing and modelling revenue rose 36%. Growth alone does not settle the question. The same quarter produced a loss from operations of USD75.9 million, and the first half of 2026 a net loss of USD120.3 million, with reported revenue growth partly reflecting acquisitions rather than the existing business. Tempus illustrates the model well precisely because both things are true at once.

Diagnostics. CareDx (NASDAQ: CDNA) and Veracyte (NASDAQ: VCYT) demonstrate how genomic information can be packaged into clinical diagnostic products. At this stage, test volumes, clinical adoption and reimbursement become central to the economics. A clinically useful test still needs sufficient payer coverage to become a scalable business.

For investors seeking broader thematic exposure, ARK Genomic Revolution ETF (ARKG) provides another approach, with exposure across multiple parts of the genomics ecosystem rather than reliance on one business model.

These businesses may all benefit from the same broad theme, but they monetise it in very different ways. That becomes increasingly relevant as investors move from established infrastructure towards data platforms, diagnostics and clinical-stage therapeutics.

From Reading DNA To Rewriting It

The most transformative part of the genomics story may be the shift from understanding genetic information to changing it. Sequencing allows researchers to identify genetic mutations and understand how they relate to disease. Gene editing seeks to go a step further by modifying DNA itself.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the companies at the forefront of this transition. Its work centres on CRISPR-based gene editing, a technology designed to make targeted changes to genetic material. Rather than simply identifying the genetic basis of disease, gene editing seeks to modify the underlying biology.

Intellia Therapeutics (NASDAQ:NTLA) is pursuing another application through in-vivo gene editing, where the editing machinery is delivered directly into the body rather than cells being removed and modified outside the patient.

This creates a fundamentally different investment proposition from established genomic infrastructure. Sequencing companies can monetise increasing usage as adoption grows, while gene-editing companies may require years of clinical development and significant capital before the commercial opportunity is established.

The progression is significant: genomics first allowed researchers to read DNA at scale; increasingly sophisticated technologies are now attempting to use that information to change biology itself.

Where the Risks Lie

The scale of the opportunity can make genomics susceptible to excessive expectations. Scientific potential does not automatically translate into shareholder value.

Clinical and regulatory. Outcomes can be binary in a way they rarely are in established industries. A single trial result or regulatory decision can materially change the prospects of a clinical-stage company, while development timelines can extend for years.

Funding and dilution. Companies without meaningful commercial revenue often need to fund lengthy development programmes through capital raises. Cash runway, operating expenditure and future funding requirements therefore become central investment considerations.

Commercial translation. Scientific validation does not equal revenue. Reimbursement decisions, clinical adoption and the cost of building a commercial organisation all sit between an approved product and a profitable business.

Technological displacement. The pace of innovation means a platform advantage is not necessarily permanent. New sequencing methods, analytical techniques or therapeutic approaches can emerge and change the competitive environment.

Valuation risk. A company can participate in a structurally attractive market while its shares already reflect a substantial proportion of the expected growth. Investors therefore need to distinguish between scientific validation, clinical validation and commercial validation.

Turning Science Into Returns

The more relevant question is no longer whether genomics has potential, but which businesses are positioned to capture it. Six tests can help separate technological promise from commercial opportunity.

• Is the technology genuinely differentiated? Investors need to understand whether a company's technology offers a meaningful advantage in accuracy, speed, cost, throughput or functionality. Intellectual property and competitive positioning also matter.
• Is there evidence of commercial adoption? Scientific validation is not enough. Investors should look for customers, clinicians or pharmaceutical partners actually paying for the technology, and for that revenue to grow.
• What is the business model? Instruments, consumables, diagnostic tests, software, data licensing and therapeutics produce very different economics. Recurring revenue from consumables or diagnostic tests behaves differently from transactional instrument sales, while neither resembles a pre-revenue therapeutics developer.
• Can the company fund the opportunity? Cash runway, operating cash burn and future capital requirements are particularly important for early-stage biotechnology businesses. A large addressable market is of limited value to existing shareholders if reaching it requires repeated dilution.
• Does the AI layer change a measurable outcome? Many genomics companies now incorporate AI into their platforms. The relevant question is whether it produces measurable improvements in discovery speed, diagnostic accuracy, research costs, clinical adoption or the value extracted from existing datasets.
• How much future success is already priced in? A differentiated technology operating in a large market can still disappoint as an investment if expectations embedded in the share price are too high. Valuation ultimately determines how much of the future opportunity investors are already paying for.

It is also useful to view genomics as a spectrum of risk rather than a single category. Established infrastructure businesses sit at one end, emerging commercial platforms in the middle and clinical-stage biotechnology at the other. They may benefit from the same broad theme, but their revenue visibility, capital requirements and risk profiles are fundamentally different.

The Genomics Opportunity

Genomics is increasingly becoming more than a scientific discipline. It is developing into a commercial ecosystem spanning sequencing, synthetic biology, single-cell analysis, diagnostics, data, AI, drug discovery and gene editing.

The most interesting part of the opportunity may be the convergence between these technologies. More genomic data creates greater demand for interpretation, while AI provides increasingly powerful tools for finding patterns within that information. Better interpretation can support improved diagnostics, more targeted drug development and, ultimately, new approaches to treatment.

For investors, however, the size of the opportunity is only the beginning. The key is identifying where durable economics are emerging within the value chain.

Genomics may prove to be a significant healthcare theme, but the businesses capable of turning that theme into sustainable revenue, cash flow and shareholder value will not necessarily be the same ones that attract the most attention.